Russell Investments Group Ltd. Trims Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Russell Investments Group Ltd. reduced its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 17.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 196,652 shares of the company’s stock after selling 41,446 shares during the period. Russell Investments Group Ltd. owned about 0.05% of Recursion Pharmaceuticals worth $1,329,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Envestnet Asset Management Inc. grew its holdings in Recursion Pharmaceuticals by 5.3% during the fourth quarter. Envestnet Asset Management Inc. now owns 231,756 shares of the company’s stock valued at $1,567,000 after purchasing an additional 11,646 shares during the period. Wells Fargo & Company MN increased its holdings in Recursion Pharmaceuticals by 298.5% in the 4th quarter. Wells Fargo & Company MN now owns 458,321 shares of the company’s stock worth $3,098,000 after acquiring an additional 343,304 shares in the last quarter. Headlands Technologies LLC raised its stake in Recursion Pharmaceuticals by 196.7% during the 4th quarter. Headlands Technologies LLC now owns 89,314 shares of the company’s stock worth $604,000 after acquiring an additional 59,211 shares during the period. Geode Capital Management LLC boosted its position in shares of Recursion Pharmaceuticals by 12.1% in the fourth quarter. Geode Capital Management LLC now owns 6,087,149 shares of the company’s stock worth $41,160,000 after purchasing an additional 655,238 shares during the period. Finally, Franklin Resources Inc. raised its position in shares of Recursion Pharmaceuticals by 299.6% during the 4th quarter. Franklin Resources Inc. now owns 75,779 shares of the company’s stock valued at $512,000 after purchasing an additional 56,816 shares during the period. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Price Performance

NASDAQ:RXRX opened at $5.50 on Monday. The business has a 50 day simple moving average of $6.62 and a 200-day simple moving average of $6.80. Recursion Pharmaceuticals, Inc. has a 1 year low of $3.79 and a 1 year high of $12.36. The firm has a market capitalization of $2.21 billion, a price-to-earnings ratio of -3.59 and a beta of 1.00. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its earnings results on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm had revenue of $4.60 million during the quarter, compared to analysts’ expectations of $19.04 million. During the same period in the prior year, the company posted ($0.42) EPS. The company’s revenue was down 57.8% compared to the same quarter last year. Equities analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Cowen reissued a “hold” rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. KeyCorp dropped their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. Needham & Company LLC restated a “buy” rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 8th. Leerink Partners dropped their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a report on Friday, February 28th. Finally, Morgan Stanley decreased their target price on Recursion Pharmaceuticals from $10.00 to $8.00 and set an “equal weight” rating on the stock in a research report on Thursday, April 10th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat, Recursion Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $8.20.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.